PTC Therapeutics is a biopharmaceutical company focused on rare genetic disorders and other specialty diseases with high unmet medical need. Its portfolio includes marketed and pipeline therapies that target conditions such as Duchenne muscular dystrophy and other inherited or neurological disorders, often using specialized small-molecule and gene-related approaches. Physicians, specialist centers and patients in rare-disease communities are its primary stakeholders.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1,176.1 | — | 866.6 | — |
| Q2 2025 | 178.9 | — | -64.8 | — |
| Q3 2025 | 211 | — | 15.9 | — |
| Q4 2025 | 164.7 | — | -135 | — |
| Q1 2026 | 272.6 | -76.8% | -2.8 | -100.3% |
| Q2 2026 | 360.5 | 101.5% | 83.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Sabra Health Care REIT, Inc. (SBRA), MiniMed Group, Inc. (MMED), Mattel, Inc. (MAT), The Middleby Corporation (MIDD), Novanta Inc. (NOVT), Eastern Bankshares, Inc. (EBC)